论文部分内容阅读
本文对肺癌患者和肺部良性疾病患者的血清β_2-微球蛋白(β_2-m)及癌胚抗原(CEA)水平作了回顾性分析,并对肺癌的不同组织类型进行了分别研究,以探讨这二种肿瘤标志物测定对肺癌的诊断价值及其临床意义。 材料和方法 一、对象: (一)肺良性疾病组:其中52例行β_2-m测定(肺结核31例,其它21例),76例行CEAi测定(肺结核55例,其它21例)。 (二)肺腺癌组:其中46例行β_2-m和CEA测定。 (三)肺鳞癌组:其中55例行β_2-m测定,52例行CEA测定。 (四)小细胞肺癌组:其中35例行β_2-m测定,37例行CEA测定。 所有患者来自本院住院病例,大多数均有二项测定结果。病例均经临床有关检查及(或)病理
This article retrospectively analyzed the serum β2-microglobulin (β_2-m) and carcinoembryonic antigen (CEA) levels in patients with lung cancer and benign lung disease, and studied the different types of lung cancer in order to explore These two tumor markers determine the diagnostic value and clinical significance of lung cancer. Materials and Methods 1. Object: (1) Benign lung diseases group: 52 cases were tested for β 2 -m (31 cases for pulmonary tuberculosis, 21 cases for other cases), and 76 cases were tested for CEAi (55 cases of tuberculosis and 21 cases of other cases). (b) Lung adenocarcinoma group: 46 of them underwent β_2-m and CEA measurements. (3) Lung squamous cell carcinoma group: 55 cases were tested for β 2 -m and 52 cases were tested for CEA. (D) small cell lung cancer group: 35 cases of β 2 -m determination, 37 cases of CEA determination. All patients were hospitalized from our hospital and most of them had two measurements. Cases are clinically relevant and/or pathological